Via Clinerion’s service, the partnership offers Massive Bio access to oncology patient insights for site outreach and identification of cohorts for trial site selection and patient recruitment. Clinerion’s Patient Network Explorer – which covers 74 million patients in 19 countries around the world – queries anonymised patient data from its international network of partner hospitals to deliver real-world health data insights useful for Massive Bio’s site outreach programmes; while it’s ANID technology allows authorised clinical trial staff to re-identify patients for screening and inclusion in trials, speeding up patient recruitment.
Massive Bio, on the other hand, provides end-to-end patient enrollment technology and services in oncology clinical trials for patients treated at community practices. These services include patient identification/engagement, pre-screening, JIT (just in time) site activation, and real-world data services. In addition, Massive Bio provides value-based compensation to pharmaceutical companies by reducing time-to-market, complexity and costs in oncology clinical trial enrollment.
“With Clinerion’s market leadership outside the US and Massive Bio’s US market leadership in oncology clinical trials, we feel that we form a powerful combination to provide global coverage and serve a global client base which creates significant growth opportunities for both enterprises,” commented Selin Kurnaz, Co-Founder and CEO of Massive Bio. “We are excited for the opportunities in front of us.”
CEO of Clinerion Ian Rentsch noted that the partnership presented a new means of improving patient experience and outcomes. He added: “Massive Bio’s specialisation in oncology offers a great opportunity for Clinerion to support cancer patients in bringing them access to international clinical research and accelerate the development of next-generation medical interventions.”